BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Business

  Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

  Takeda announced financial results for the third quarter of fiscal year 2023. With year-to-date strong momentum in its Growth & Launch Products offsetting the significant revenue impact of generic entrants, Takeda remains on track towards its full-year Management Guidance.

  February 1, 2024

   · 

  11 min read
• Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

  Kuros Biosciences, a leader in next generation bone graft technologies, announced it will present at the CG 2024 Musculoskeletal Conference, to be held in San Francisco on February 12, 2024.

  February 1, 2024

   · 

  3 min read
• Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

  Strong pipeline including record 12 blockbuster opportunities under clinical evaluation detailed at recent R&D Day.

  February 1, 2024

   · 

  4 min read
• Business

  Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

  François-Xavier Roger will be appointed Chief Financial Officer and a member of Sanofi’s Executive Committee effective April 1, 2024.

  February 1, 2024

   · 

  3 min read
• Drug Development

  Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation

  Sensorion announces the recruitment of the last patient in its Phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation.

  February 1, 2024

   · 

  5 min read
• Business

  Legacy Novozymes delivers solid last full-year results

  In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 25.4%, and ROIC including goodwill before special items* of 16.5%.

  February 1, 2024

   · 

  2 min read
• Business

  HUTCHMED to Announce 2023 Final Results

  HUTCHMED Limited will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time / 11:30 am Greenwich Mean Time / 7:30 pm Hong Kong Time.

  February 1, 2024

   · 

  1 min read
• Business

  Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO

  Maxion Therapeutics announced that Dr Arndt Schottelius has been appointed as the new Chief Executive Officer, effective on 1 March 2024, to take the Company to its next phase of development.

  February 1, 2024

   · 

  4 min read
• Policy

  Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

  Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.

  February 1, 2024

   · 

  2 min read
• LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million

  LimmaTech Biologics announced a second closing of its Series A financing, raising an additional USD 3 million from new investor Tenmile, bringing the total raised to USD 40 million.

  February 1, 2024

   · 

  3 min read